Showing results (391-400 of 439) with videos related to

Sort By:
Pageof 44
Human Immunology|August 1, 1984
Characterization and expression of the HLA-DC antigens defined by anti-Leu 10Y X Chen, R L Evans, M S Pollack, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1993
A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancerV W Lee, E J Sax, D B McAneny, et al.
Cancer Immunology, Immunotherapy : CII|November 25, 2000
Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptidesB W Anderson, A P Kudelka, T Honda, et al.
American Journal of Respiratory Cell and Molecular Biology|April 18, 2001
Overexpression of manganese superoxide dismutase protects lung epithelial cells against oxidant injuryA M Ilizarov, H C Koo, J A Kazzaz, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1983
HLA genotyping in family members and patients with familial polycystic ovarian diseaseF P Mandel, R J Chang, B Dupont, et al.
Blood|May 1, 1980
Fatal graft-versus-host disease following blood transfusion in Hodgkin's disease documented by HLA typingR E Dinsmore, D J Straus, M S Pollack, et al.
Blood|February 1, 1983
Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cellsY Reisner, N Kapoor, D Kirkpatrick, et al.
The New England Journal of Medicine|October 26, 1978
Genetic mapping of the 21-hydroxylase-deficiency gene within the HLA linkage groupL S Levine, M Zachmann, M I New, et al.
HIV Clinical Trials|June 27, 2006
Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participantsS L Pett, H Wand, M G Law, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancerManuel Hidalgo, Jan C Buckner, Charles Erlichman, et al.
Pageof 44